Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world
NCT05022342
·
clinicaltrials.gov ↗
COMPLETED
Status
595
Enrollment
INDUSTRY
Sponsor class
Conditions
Breast Cancer
Interventions
OTHER:
alpelisib plus fulvestrant
Sponsor
Novartis Pharmaceuticals